TNFA-863 polymorphism is associated with a reduced risk of Chronic Obstructive Pulmonary Disease: A replication study
© Córdoba-Lanús et al; licensee BioMed Central Ltd. 2011
Received: 4 April 2011
Accepted: 10 October 2011
Published: 10 October 2011
TNF-α mediated inflammation is thought to play a key role in the respiratory and systemic features of Chronic Obstructive Pulmonary Disease. The aim of the present study was to replicate and extend recent findings in Taiwanese and Caucasian populations of associations between COPD susceptibility and variants of the TNFA gene in a Spanish cohort.
The 3 reported SNPs were complemented with nine tag single nucleotide polymorphisms (SNP) of the TNFA and LTA genes and genotyped in 724 individuals (202 COPD patients, 90 smokers without COPD and 432 healthy controls). Pulmonary function parameters and serum inflammatory markers were also measured in COPD patients.
The TNFA rs1800630 (-863C/A) SNP was associated with a lower COPD susceptibility (ORadj = 0.50, 95% CI = 0.33-0.77, p = 0.001). The -863A allele was also associated with less severe forms of the disease (GOLD stages I and II) (ORadj = 0.303, 95%CI = 0.14-0.65, p = 0.014) and with lower scores of the BODE index (< 2) (ORadj = 0.40, 95%CI = 0.17-0.94, p = 0.037). Moreover, the -863A carrier genotype was associated with a better FEV1 percent predicted (p = 0.004) and a lower BODE index (p = 0.003) over a 2 yrs follow-up period. None of the TNFA or LTA gene variants correlated with the serum inflammatory markers in COPD patients (p > 0.05).
We replicated the previously reported association between the TNFA -863 SNP and COPD. TNFA -863A allele may confer a protective effect to the susceptibility to the disease in the Spanish population.
Tumour necrosis factor alpha (TNF-α) is critical in the regulation of inflammation by inducing a cascade of other inflammatory cytokines, chemokines, and other growth factors . The results of several in vitro and in vivo investigations indicate that high-level generation of TNF-α leads to an exacerbation of the inflammatory and pro-oxidative responses that are important in the pathogenesis of many diseases. TNF-α mediated inflammation is thought to play a key role in both the respiratory and systemic features of Chronic Obstructive Pulmonary Disease (COPD) .
Higher concentration of TNF-α has been reported in induced sputum in stable COPD patients and during exacerbations. This cytokine was also found increased in bronchial biopsies and bronchoalveolar lavage fluid of COPD patients when compared with control subjects . A meta-analysis study found higher circulating TNF-α levels in COPD patients when compared to controls  and these were also related with important weigh loss in severe patients .
Genetic variation in the promoter region of TNFA (chromosome 6p21) has been associated with different phenotype expressions, and a wide range of autoimmune, infectious, and oncologic diseases . A common G-to-A single nucleotide polymorphism (SNP) at position -308 (rs1800629), directly affects gene regulation and has been associated with increased transcriptional activity of TNFA in various disorders [6, 7]. This polymorphism has been studied in several COPD related phenotypes, with contradictory results. It has also been associated with chronic bronchitis and an increased risk of airflow obstruction in Asian populations [8, 9]. Most studies in Caucasian populations could not demonstrate this association [10–13]. Only two studies showed an association of the -308 SNP and COPD, the first being a large family study from the Boston early-onset COPD study (2006) and the second performed by Gingo and colleagues (2008) found an increased risk of the A allele of being associated with the disease [14, 15].
A 2010 study performed in Taiwanese individuals identified TNF -863A (rs1800630) variant to be associated less frequently with COPD .
The neighbouring gene, lymphotoxin alpha (LTA) has also been related to alter TNF-α expression. TNF-α and LT-α are proinflammatory cytokines coded for by the TNFA and LTA genes, respectively, mediating a large variety of inflammatory and immunostimulatory responses. The +252 (A to G) SNP in the LTA gene has received attention due to its supposed implication in gene regulation  and reported associations with several diseases [18, 19]. Higher levels of TNF-α have been reported to be associated with SNPs in the LTA gene . A case-control study performed on a Russian population reported +252G allele to be associated with a subgroup of severe COPD patients . There is only one study exploring the association of SNPs in both genes and lung function in smokers with mild-to-moderate airway obstruction .
The aim of the present study was to replicate recent findings in Taiwanese and Caucasian populations of associations between COPD susceptibility and variants (rs1800629, rs361525 and rs1800630) of the TNFA gene in a Spanish cohort. We further aimed to extend on these findings by assessing whether variants/haplotypes of the entire TNFA and LTA genes may influence COPD susceptibility, severity and lung function decline in a Spanish cohort.
Caucasian individuals included in this study were divided into three groups, COPD patients, smokers without COPD and healthy controls. COPD outpatients were recruited from a pulmonary clinic at the Hospital Universitario N. S. de Candelaria (Canary Islands, Spain) from August 2002 to July 2009. Patients with a wide range of disease severity were included using the following criteria: age > 40 years, smoking history > 10 pack-years and a post-bronchodilator FEV1/FVC ratio < 0.70 measured 20 min after the administration of 400 mg of inhaled albuterol. Pulmonary function tests were measured according to GOLD guidelines . The arterial oxygen tension (PaO2) was measured at rest. Severe hypoxemia was defined by PaO2 values < 60 mmHg. Exercise capacity was also tested using the best of two 6-min walking distance (6MWD) tests separated by at least 30 min following the ATS recommendations . The body mass index (BMI) was calculated as the weight in kilograms divided by the square of the height in meters. The BODE (Body Mass Index, Airflow Obstruction, Dyspnea, Exercise Performance) Index was calculated as previously described . All patients were clinically stable (no exacerbation for at least 2 months) at the time of evaluation. Patients were excluded if they had history of other diseases like asthma or bronchiectasis. As a control group we included 432 individuals without respiratory disease and no smoking history from an ongoing general adult population cohort named CDC project in the Canary Islands . Finally, the third group included 90 current smokers with a cumulative smoking history of > 15 pack-years and normal lung function (FEV1% pred > 0.80; FEV1/FVC > 0.70). In order to minimize any possible effect of population structure on our estimations, cases and controls were recruited if they have at least two generations of Canarian ancestry .
The Ethics Committee of Clinical Investigation of the Hospital approved this study (approval N°36) and written informed consents were obtained from all subjects.
SNPs selection and genotyping
We selected the haplotype-tagging SNPs in the TNFA and LTA genes using the resequencing data of the European individuals from the SeattleSNPs database http://pga.gs.washington.edu. A multimarker tagging algorithm with criteria of r2 > 0.8 and minor allele frequency (MAF) ≥ 0.1 were used with the Haploview program (version 3.2) . Eleven SNPs in the TNFA gene (GenBank, AY066019) and LTA gene (GenBank AY070490) were chosen. TNFA -857, -376 and -238 SNPs (rs1799724, rs1800750 and rs361525) were included in the study because they had been reported as susceptibility locus in other diseases [28–30].
Venous blood was collected from each individual and total genomic DNA was extracted using the commercially available GFX Kit (GE Healthcare). All tSNPs selected were genotyped using SNaPshot® SNP Genotyping Assay (Applied Biosystems, Foster City, CA). Genotyping was blind to case or control status of samples. A random 20% of the samples were genotyped in duplicate for quality control. The concordance rate for the duplicate samples was 100%. Moreover, as a confirmational method a random number of samples (patients and control subjects) was genotyped by direct sequencing on an ABI PRISM 310 Genetic Analyser (Applied Biosystems). Samples not yielding the genotypes of all SNPs were excluded from analysis; so 721 individuals remained in the study (199 COPD cases).
COPD patients' serum was separated from whole blood by centrifugation (3200 rpm) and aliquots were stored at -80°C until laboratory analysis. Circulating levels of IL-6, IL-8, IL-16, TNF-α, MCP-1, MMP-9, PARC and VEGF were measured by ELISA (R&D System, Minneapolis) according to manufacter's instructions. The detection limits were 0.7 pg/ml, 3.5, 6.2, 5.0, 156, 10, and 5.0, respectively. The within-assay coefficient of variation for all assays was less than 10%.
Demographic characteristics of COPD patients, smokers and healthy individuals included in the association study
Cases (n = 202)
Smoking controls (n = 90)
Healthy controls (n = 432)
Gender (male %)
62 ± 10
48 ± 9
53 ± 8
Smoking history(pack-yrs) † *
63 ± 27
35 ± 18
FEV 1 *
1.53 ± 0.7
3.06 ± 0.71
FEV 1 % pred*
56 ± 22
102 ± 15
FVC % pred*
86 ± 23
108 ± 16
FEV 1 /FVC*
52 ± 12
79 ± 6
6MWD (m) *
490 ± 86
BMI (Kg/m 2 )*
27 ± 5
2 ± 0.7
BODE index < 2 ‡
BODE index ≥ 3 ‡
GOLD I-II ‡
GOLD III-IV ‡
Table 1 summarizes the demographic data and baseline characteristics of the study groups. Of the 202 stable COPD patients (153 men and 49 women), 59% of patients were in GOLD stages I-II and 41% in GOLD stages III-IV. Similarly, of the 163 patients where the BODE index was possible to calculate, 68% scored < 2 in the BODE index and 32% scored higher (BODE ≥ 3).
Association of SNPs in the LTA and TNFA genes with Chronic Obstructive Pulmonary Disease (COPD)
COPD cases vs. healthy control
Seattle SNP database
COPD cases MAF %
Healthy controls MAF %
ORadj (95% CI) a
Association tests of TNFA -863 C/A polymorphism with COPD using multiple logistic regression analysis
BODE < 2 vs BODE ≥ 3
Longitudinal association of TNFA -863 polymorphism with pulmonary function and BODE index in COPD patients
FEV1 % pred
55.2 ± 20.1
52.1 ± 18.7
49.1 ± 19.7
64.9 ± 21.6
61.3 ± 19.4
62.0 ± 17.1
The obtained p-values were corrected for multiple testing by the effective number of independent tests (8.85) resulting in a significant association for allele A carriers of the -863 SNP between the COPD cases and the healthy controls group (adjusted p = 0.02). No significant differences were found in COPD patients versus smokers without the disease when analysing single polymorphisms.
Haplotype frequency of the LTA and TNFA genes SNPs in COPD patients vs. Healthy control individuals
Healthy controls n = 432
COPD cases n = 199
A A T C C C G G G G
C A C C A C G G G G
0.70 (0.45 - 1.08)
C G T A C C G A G G
1.03 (0.64 - 1.66)
C G T A C C G G G G
1.09 (0.67 - 1.78)
C A C C C C G G G G
1.27 (0.72 - 2.23)
A A T C C T G G G A
1.33 (0.76 - 2.35)
C A C C C C A G A G
1.74 (0.75 - 4.00)
C A C C C C G G A G
1.54 (0.59 - 4.02)
C A T C C C G G G G
1.59 (0.56 - 4.48)
None of the TNFA or LTA gene variants analysed in the present study resulted correlated with the circulating IL-6, IL-8, IL-16, TNF-α, MCP-1, MMP-9, PARC or VEGF levels in serum of COPD patients (p > 0.05, data not shown).
Our objective was to replicate results from previous studies [14–16] showing association between TNF polymorphisms and COPD. The present study investigates the association of TNFA and LTA genes polymorphisms and COPD presence and severity including eleven SNPs of two genes that cover most of their variability. The most important finding of our research suggests that the previously reported TNFA -863A allele is less frequent in COPD patients. The presence of this allele was associated with a less severe form of the disease (GOLD stages I-II) and with lower scores of the BODE index (< 2). Moreover, this association remained unchanged after adjustment for confounding factors like age and gender, suggesting a robust effect.
The most recent study, performed in Taiwanese individuals, found that the -863A allele was associated less frequently with COPD, with an increased FEV1/FVC ratio and higher BMI among heavy smokers . Another two studies on COPD found an association of the haplotype containing the -863A variant with a lower risk for susceptibility to COPD, one performed on a Greek population  and the second performed on a Caucasian one . Similarly, in our study the only haplotype that contains the -863A allele also tended to be less likely in COPD patients. This region of the TNFA promoter seems to affect transcription factors binding capacity. The variant -863 has been reported to specifically reduce 10 fold the binding affinity of the transcription nuclear factor (NF-κB) specially the form p-50-p50 . Most of the inflammatory proteins that are up regulated in airways of COPD patients are regulated by the transcription nuclear factor NF-κB that is activated in alveolar macrophages of COPD patients . The -863A allele has been reported associated with elevated TNF-α production by peripheral blood mononuclear cells stimulated with concavalin A  while others have associated this variant with reduced circulating levels of the cytokine [30, 39]. In the present analysis we could not find any relation between the SNP and serum levels of TNF-α or any other inflammatory cytokine measured.
One strength of the present study is that the association found for the -863 SNP and FEV1 and BODE index was also replicated when we explored the SNP association in the three longitudinal clinical measures registered over the two years follow up period. This is the first report of a case-control study that evaluated the influence of gene variants on clinical and pulmonary function longitudinal data in a cohort of COPD patients.
However, we did not replicate other previously reported [14, 15] associations of TNF polymorphisms with the disease. Consistent with the majority of previous studies on Caucasians we found that the most studied TNFA polymorphism (-308G/A) was not associated with the presence of COPD in our sample. Only two studies on Caucasians found significant association between this SNP and COPD presence. The first was a family based research from the Boston Early Onset COPD study  that analysed 17 families but these findings could not be replicated in a case control study of later onset COPD patients. The second, a case-control study , found that the -308A allele had a higher risk of being associated with COPD and was also associated with worse FEV1/FVC. In that study the authors included as cases a subgroup of 11 individuals with emphysema that did not met COPD diagnosis criteria, and therefore this subgroup may have influence the final results. In addition, a meta-analysis study performed by Smolonska and colleagues  reported that TNFA was found associated with COPD susceptibility only in Asians.
In relation to other SNPs within the two genes analysed in previous studies, none of them were found associated with COPD in the present study. This finding is supported by the results obtained by the majority of researches performed in Caucasian individuals [10–15, 40].
The present study has several limitations. Firstly, the reduced sample size of the smoking control group without the disease cannot exclude that the lack of association found between cases and smokers without COPD with the -863 SNP could be a false negative result due to a type II error. The present analysis should be tested in a large sample of smoking controls. Second, population stratification should be addressed in this kind of studies. Even though, it is known that human populations from Spain, including Canary Islands, are highly homogenous in their genetic background , in order to reduce the possibility of subtle population stratification we included 100% Canarian individuals in our control groups (smokers and non-smokers) with at least two generations of ancestors from the islands. And third, we have not find correlation between the genetic variants analysed and the functional aspects of the progression of the disease probably due to the short observational period of our study. Mayor long-term longitudinal studies are needed in order to confirm the relationships of certain factors with clinical and functional variables of the disease.
We have found that COPD patients with the variant -863A presented better lung function (GOLD stages I-II). The -863A allele may be conferring a protective effect on the progression of the disease, which could be explained by the fact that COPD patients progress in different manner along time. It has been hypothesized that the disease progression could be represented by three steps suggesting that, in most smokers the disease process will not advance if innate inflammation is minimized which situate individuals at step 1 or 2 of the model, which is comparable to smokers with normal lung function or COPD patients at GOLD stage I and II respectively . This may be the consequence of a genetic background that protects smokers in progressing to severe forms of the disease as it is shown by our results.
Our data confirm a previous study where the minor allele of SNP -863 in the TNFA gene was associated with a reduced risk of COPD. Our findings also suggest that the-863A allele is associated with less severe forms of the disease. No association was observed for other SNPs in TNF-LT genes and COPD. This is the first study of TNFA and LTA gene polymorphisms in COPD performed in a Spanish Population.
American Thoracic Society
Body Mass Index
Body Mass Index, Airflow Obstruction, Dyspnea, Exercise Performance
Chronic Obstructive Pulmonary Disease
Forced Vital Capacity
Minor Allele Frequency
Single Nucleotide Polymorphism
6-Min Walking Distance
Tumour Necrosis Factor Alpha
Tag Single Nucleotide Polymorphism.
This research was supported by grants of the Fundación Canaria de Investigación y Salud (FUNCIS 55/04), Fondo de Investigación Sanitaria (FIS 06/1144) and Sociedad Española de Patología Respiratoria (SEPAR 2005). The authors thank Angela Montejo de Garcini, Candelaria González Díaz and Violeta Cazaña for their excellent technical assistance.
- Wouters EF, Reynaert NL, Dentener MA, Vernooy JH: Systemic and local inflammation in asthma and chronic obstructive pulmonary disease: is there a connection?. Proc Am Thorac Soc. 2009, 6: 638-647. 10.1513/pats.200907-073DP.View ArticlePubMedGoogle Scholar
- Mukhopadhyay S, Hoidal JR, Mukherjee TK: Role of TNFα in pulmonary pathophysiology. Respir Res. 2006, 7: 125-10.1186/1465-9921-7-125.View ArticlePubMedPubMed CentralGoogle Scholar
- Chung KF: Cytokines in chronic obstructive pulmonary disease. Eur Respir J. 2001, 50s-59s. Suppl 34
- Gan WQ, Man SF, Senthilselvan A, Sin DD: Association between chronic obstructive pulmonary disease and systemic inflammation: a systematic review and a metaanalysis. Thorax. 2004, 59: 574-580. 10.1136/thx.2003.019588.View ArticlePubMedPubMed CentralGoogle Scholar
- de Godoy I, Donahoe M, Calhoun WJ, Mancino J, Rogers RM: Elevated TNF-a production by peripheral blood monocytes of weight-losing COPD patients. Am J Respir Crit Care Med. 1996, 53: 633-637.View ArticleGoogle Scholar
- Wilson AG, Symons JA, McDowell TL, McDevitt HO, Duff GW: Effects of a polymorphism in the human tumour necrosis factor a promoter on transcriptional activation. Proc Natl Acad Sci USA. 1997, 94: 3195-3199. 10.1073/pnas.94.7.3195.View ArticlePubMedPubMed CentralGoogle Scholar
- Wu WS, McClain KL: DNA polymorphisms and mutations of the tumor necrosis factor-a (TNF-a) promoter in Langerhans cell histiocytosis (LCH). J Interferon Cytokine Res. 1997, 17: 631-635. 10.1089/jir.1997.17.631.View ArticlePubMedGoogle Scholar
- Huang SL, Su CH, Chang SC: Tumour necrosis factor-alpha gene polymorphism in chronic bronchitis. Am J Respir Crit Care Med. 1997, 156: 436-1439.View ArticleGoogle Scholar
- Sakao S, Tatsumi K, Igari H, Shino Y, Shirasawa H, Kuriyama T: Association of tumor necrosis factor alpha gene promoter polymorphism with the presence of chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2001, 163: 420-422.View ArticlePubMedGoogle Scholar
- Brøgger J, Steen VM, Eiken HG, Gulsvik A, Bakke P: Genetic association between COPD and polymorphisms in TNF, ADRB2 and EPHX1. Eur Respir J. 2006, 27: 682-688. 10.1183/09031936.06.00057005.View ArticlePubMedGoogle Scholar
- Seifart C, Dempfle A, Plagens A, Seifart U, Clostermann U, Müller B, Vogelmeier C, von Wichert P: TNF-a-, TNF-b-, IL- 6-, and IL-10-promoter polymorphisms in patients with chronic obstructive pulmonary disease. Tissue Antigens. 2005, 65: 93-100. 10.1111/j.1399-0039.2005.00343.x.View ArticlePubMedGoogle Scholar
- Tanaka G, Sandford AJ, Burkett K, Connett JE, Anthonisen NR, Paré PD, He JQ: Tumour necrosis factor and lymphotoxin A polymorphisms and lung function in smokers. Eur Respir J. 2007, 29: 34-41.View ArticlePubMedGoogle Scholar
- Chappell S, Daly L, Morgan K, Baranes TG, Roca J, Rabinovich R, Millar A, Donnelly SC, Keatings V, Macnee W, Stolk J, Hiemstra PS, Miniati M, Monti S, O'Connor CM, Kalsheker N: Variation in the tumour necrosis factor gene is not associated with susceptibility to COPD. Eur Respir J. 2007, 30: 810-2. 10.1183/09031936.00057107.View ArticlePubMedGoogle Scholar
- Gingo MR, Silveira LJ, Miller YE, Friedlander AL, Cosgrove GP, Chan ED, Maier LA, Bowler RP: Tumour necrosis factor gene polymorphisms are associated with COPD. Eur Respir J. 2008, 31: 1005-1012. 10.1183/09031936.00100307.View ArticlePubMedGoogle Scholar
- Hersh CP, Demeo DL, Lange C, Litonjua AA, Reilly JJ, Kwiatkowski D, Laird N, Sylvia JS, Sparrow D, Speizer FE, Weiss ST, Silverman EK: Attempted replication of reported chronic obstructive pulmonary disease candidate gene associations. Am J Respir Cell Mol Biol. 2005, 33: 71-78. 10.1165/rcmb.2005-0073OC.View ArticlePubMedPubMed CentralGoogle Scholar
- Chen YC, Liu SF, Chin CH, Wu CC, Chen CJ, Chang HW, Wang YH, Chung YH, Chao TY, Lin MC: Association of Tumour Necrosis Factor-alpha-863C/A Gene Polymorphism with Chronic Obstructive Pulmonary Disease. Lung. 2010, 188: 339-47. 10.1007/s00408-010-9236-5.View ArticlePubMedGoogle Scholar
- Messer G, Spengler U, Jung MC, Honold G, Blömer K, Pape GR, Riethmüller G, Weiss EH: Polymorphic structure of the tumor necrosis factor (TNF) locus: an NcoI polymorphism in the first intron of the human TNF-b gene correlates with a variant amino acid in position 26 and a reduced level of TNF-b production. J Exp Med. 1991, 173: 209-219. 10.1084/jem.173.1.209.View ArticlePubMedGoogle Scholar
- Migita O, Noguchi E, Koga M, Jian Z, Shibasaki M, Migita T, Ito S, Ichikawa K, Matsui A, Arinami T: Haplotype analysis of a 100 kb region spanning TNF-LTA identifies a polymorphism in the LTA promoter region that is associated with atopic asthma susceptibility in Japan. Clin Exp Allergy. 2005, 35: 790-796. 10.1111/j.1365-2222.2005.02265.x.View ArticlePubMedGoogle Scholar
- Hogg JC, Chu F, Utokaparch S, Woods R, Elliott WM, Buzatu L, Cherniack RM, Rogers RM, Sciurba FC, Coxson HO, Paré PD: The nature of small airway obstruction in chronic obstructive pulmonary disease. N Engl J Med. 2004, 350: 2645-2653. 10.1056/NEJMoa032158.View ArticlePubMedGoogle Scholar
- Tomasdottir H, Hjartarson H, Ricksten A, Wasslavik C, Bengtsson A, Ricksten SE: Tumour necrosis factor gene polymorphism is associated with enhanced systemic inflammatory response and increased cardiopulmonary morbidity after cardiac surgery. Anesth Analg. 2003, 97: 944-949.View ArticlePubMedGoogle Scholar
- Danilko KV, Korytina GF, Akhmidishina LZ, Ianbaeva DG, Zagidullin ShZ, Victorova TV: Association of cytokines genes (ILL, IL1RN, TNF, LTA, IL6, IL8, IL0) polymorphic markers with chronic obstructive pulmonary disease. Mol Biol (Mosk). 2007, 41: 26-36.View ArticleGoogle Scholar
- Rabe KF, Hurd S, Anzueto A, Barnes PJ, Buist SA, Calverley P, Fukuchi Y, Jenkins C, Rodriguez-Roisin R, van Weel C, Zielinski J: Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med. 2007, 176: 532-555. 10.1164/rccm.200703-456SO.View ArticlePubMedGoogle Scholar
- ATS Statement: Guidelines for the Six-Minute Walk Test. Am J Resp Crit Care Med. 2002, 166: 111-117.View ArticleGoogle Scholar
- Celli BR, Cote C, Marin JM, Casanova C, Montes de Oca M, Mendez RA, Pinto Plata V, Cabral HJ: The Body Mass Index, Airflow Obstruction, Dyspnea, Exercise Performance (BODE) Index in Chronic Obstructive Pulmonary Disease. N Engl J Med. 2004, 350: 1005-1012. 10.1056/NEJMoa021322.View ArticlePubMedGoogle Scholar
- Cabrera de León A, González DA, Méndez LI, Aguirre-Jaime A, del Cristo Rodríguez Pérez M, Coello SD, Trujillo IC: Leptin and altitude in the cardiovascular diseases. Obes Res. 2004, 12: 1492-1498. 10.1038/oby.2004.186.View ArticlePubMedGoogle Scholar
- Maca-Meyer N, Villar J, Pérez-Méndez L, Cabrera de León A, Flores C: A tale of aborigines, conquerors and slaves: Alu insertion polymorphism ante peopling of Canary Islands. Ann Hum Genet. 2004, 68: 600-605. 10.1046/j.1529-8817.2003.00125.x.View ArticlePubMedGoogle Scholar
- Barret JC, Fry B, Maller J, Daly MJ: Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics. 2005, 21: 263-265. 10.1093/bioinformatics/bth457.View ArticleGoogle Scholar
- Martínez A, Rubio A, Urcelay E, Fernández-Arquero M, De Las Heras V, Arroyo R, Villoslada P, Montalbán X, De La Concha EG: TNF-376A marks susceptibility to MS in the Spanish population: A replication study. Neurology. 2004, 62: 809-810.View ArticlePubMedGoogle Scholar
- Van Heel DA, Udalova IA, De Silva AP, McGovern DP, Kinouchi Y, Hull J, Lench NJ, Cardon LR, Carey AH, Jewell DP, Kwiatkowski D: Inflammatory bowel disease is associated with a TNF polymorphism that affects an interaction between the OCT1 and NF-kB transcription factors. Hum Mol Genet. 2002, 11: 1281-1289. 10.1093/hmg/11.11.1281.View ArticlePubMedGoogle Scholar
- Huizinga TW, Westendorp RG, Bollen EL, Keijsers V, Brinkman BM, Langermans JA, Breedveld FC, Verweij CL, van de Gaer L, Dams L, Crusius JB, García-Gonzalez A, van Oosten BW, Polman CH, Peña AS: THF-alpha promoter polymorphisms, production and susceptibility to multiple sclerosis in different group of patients. J Neuroimmunol. 1997, 72: 149-153. 10.1016/S0165-5728(96)00182-8.View ArticlePubMedGoogle Scholar
- Raymond M, Rousset F: GENEPOP (version 1.2): population genetics software for exact tests and ecumenecism. J Hered. 1995, 86: 248-249.Google Scholar
- Stephens M, Donnelly P: A comparison of Bayesian methods for haplotype reconstruction. Am J Hum Genet. 2003, 73: 1162-1169. 10.1086/379378.View ArticlePubMedPubMed CentralGoogle Scholar
- Sole X, Guino E, Valls J, Iniesta R, Moreno V: SNPStats: a web tool for the analysis of association studies. Bioinformatics. 2006, 22: 1928-1929. 10.1093/bioinformatics/btl268.View ArticlePubMedGoogle Scholar
- Nyholt DR: A simple correction for multiple testing for SNPs in linkage disequilibrium with each other. Am J Hum Genet. 2004, 74: 765-769. 10.1086/383251.View ArticlePubMedPubMed CentralGoogle Scholar
- Papatheodorou A, Latsi P, Vrettou C, Dimakou A, Chroneou A, Makrythanasis P, Kaliakatsos M, Orfanidou D, Roussos C, Kanavakis E, Tzetis M: Development of a novel microarray methodology for the study of SNPs in the promoter region of the TNF-alpha gene: their association with obstructive pulmonary disease in Greek patients. Clin Biochem. 2007, 40: 843-850. 10.1016/j.clinbiochem.2007.03.024.View ArticlePubMedGoogle Scholar
- Udalova IA, Nedospasov SA, Webb GC, Chaplin DD, Turetskaya RL: Highly informative typing of the human TNF locus using six adjacent polymorphic markers. Genomics. 1993, 16: 180-186. 10.1006/geno.1993.1156.View ArticlePubMedGoogle Scholar
- Barnes PJ, Shapiro SD, Pauwels RA: Chronic obstructive pulmonary disease: molecular and cellular mechanisms. Eur Respir J. 2003, 22: 672-688. 10.1183/09031936.03.00040703.View ArticlePubMedGoogle Scholar
- Higuchi T, Seki N, Kamizono S, Yamada A, Kimura A, Kato H, Itoh K: Polymorphism of the 59-flanking region of the human tumor necrosis factor (TNF)-alpha gene in Japanese. Tissue Antigens. 1998, 51: 605-612. 10.1111/j.1399-0039.1998.tb03002.x.View ArticlePubMedGoogle Scholar
- Skoog T, van't Hooft FM, Kallin B, Jovinge S, Boquist S, Nilsson J, Eriksson P, Hamsten A: A common functional polymorphism (C-A substitution at position -863) in the promoter region of the tumour necrosis factor-a (TNF-a) gene associated with reduced circulating levels of TNF-a. Hum Mol Genet. 1999, 8: 1443-1449. 10.1093/hmg/8.8.1443.View ArticlePubMedGoogle Scholar
- Smolonska J, Wijmenga C, Postma DS, Boezen HM: Meta-analyses on suspected chronic obstructive pulmonary disease genes: a summary of 20 years' research. Am J Respir Crit Care Med. 2009, 180: 618-631. 10.1164/rccm.200905-0722OC.View ArticlePubMedGoogle Scholar
- Cosio MG, Saetta M, Agusti A: Immunologic aspects of chronic obstructive pulmonary disease. N Engl J Med. 2009, 360: 2445-2454. 10.1056/NEJMra0804752.View ArticlePubMedGoogle Scholar
- The pre-publication history for this paper can be accessed here:http://www.biomedcentral.com/1471-2350/12/132/prepub
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.